JfW PTO/SB/21 (09-04)

PTO/SB/21 (09 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ter the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 10/750,353 Filing Date TRANSMITTAL December 31, 2003 NOV 2 First Named Inventor **FORM** RODI, C Art Unit 1711 **Examiner Name** To Be Assigned (to be used for all correspondence after initial filing) Attorney Docket Number RPI-1001-UT Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund **Express Abandonment Request** CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) SB08 - 1 page Transmittal in duplicate - 2 pages Reply to Missing Parts/ cover letter - 2 pages Incomplete Application post card Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Date

Reg. No.

47.608

BioTechnology Law Group

orunlow 200

Bruce Grant

Signature

Date

Printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<u>S/N 10/750,353</u> <u>PATENT</u>



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RODI, C. et al. Examiner: To Be Assigned

Serial No.: 10/750,353 Group Art Unit: 1711
Filed: December 31, 2003 Docket: RPI-1001-UT

Title: BINDINGZYME ARRAYS AND HIGH-THROUGHPUT PROTEOMIC METHODS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits. Accordingly, it is respectfully submitted no fees are due.

If any fees are due, please contact the undersigned attorney at (858) 623-9470.

INFORMATION DISCLOSURE STATEMENT

Serial No.: 10/750,353

Filing Date: December 31, 2003

Title: Bindingzyme Arrays and High-Throughput Proteomic Methods

Page 2 Dkt: RPI-1001-UT

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date 23 Novulor 201

BioTechnology Law Group 658 Marsolan Ave.

Solana Beach, CA 92075

Telephone: (858) 623-9470

Fax: (858) 623-9476

Email: bruce@biotechnologylawgroup.com

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

23 Horman 2003

gnature

Bruce Grant

Printed Name

10/750,353PTO/SB/08A(08-03)
Approved for use through 07/31/2006. OMB 0651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

1

Substitute for form 1449A/PTO	Complete if Known	quired to respond to a collection of information unless it contains a valid OMB control number
INFORMATION DISCLOSURE	Application Number	10/750,353
STATEMENT BY APPLICANT O PROPERTY OF THE PROPE	Filing Date	12/31/2003
	First Named Inventor	RODI, Charles
	Group Art Unit	1711
	Examiner Name	To Be Assigned
Sheet 1 of 1	Attorney Docket No: R	PI-1001-UT

US PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines,Where Relevant Passages or Relevant Figures Appear
	A1.	2003/0170855	09/11/2003	Zhang et al	
	A2.				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A3.					

	OTHE	ER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A4.	Holsinger et al., Oncogene 21:7067 -7076 (2002)	
	A5.		